Personalizing
Cancer Treatment for Everyone

Overall Survival Rate Increased in Gastric Cancer

Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients

November 13, 2017

By Arturo Loaiza-Bonilla, MD, MSEd

Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients with resectable gastric or gastroesophageal juncture (GEJ) cancer, according to a study reported at the European Society for Medical Oncology conference in Madrid.

The combination of docetaxel, oxaliplatin, and fluorouracil-leucovorin (FLOT) led to a median overall survival of 50 months versus 35 months for the long-time standard of epirubicin and cisplatin combined with fluorouracil or capecitabine. The difference represented a 23% reduction in the hazard ratio (P=0.012). Analysis of PFS also showed a significant advantage for FLOT, 30 versus 18 months (HR 0.75, P=0.001).
Multivariate, subgroup, and sensitivity analyses confirmed the primary results. Factors associated with improved survival were FLOT therapy (HR 0.75, P=0.005), stomach as the primary site (HR 0.74, P=0.005), and negative nodes (HR 0.72, P=0.022). The survival benefit was most pronounced among patients with Siewert type 1 esophageal tumors (HR 0.64), Barrett tumors (HR 0.62), small tumors (HR 0.66), and node-negative tumors (HR 0.64).
Loaiza-Bonilla is affiliated with Cancer Treatment Centers of America.

Click here to see orginal article

Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us by one of the options listed below:
PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top